Home » Newsletters » BioWorld

BioWorld

Aug. 16, 1995

View Archived Issues

BRISTOL-MYERS PAYING SOMATIX $20M FOR RIGHTS TO CANCER DEALS

VICAL LOOKS TO RAISE $29.7M IN PUBLIC OFFERING OF 2.5M SHARES

AMGEN LICENSES RIGHTS TO NOVO NORDISK'S TPO

$35M TO FLEDGLING GENOVO

DEVICE EXPRESSES BLOOD-BOOSTING EPO IN RATS NOW, PEOPLE LATER

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 17, 2024.
Second insulin receptor offers new therapeutic avenues
BioWorld Science
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...
Mechanism underlying so-called idiopathic autism inception unveiled
BioWorld Science
Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.